Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hajeong | - |
dc.contributor.author | Kang, Eunjeong | - |
dc.contributor.author | Kang, Hee Gyung | - |
dc.contributor.author | Kim, Young Hoon | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Kim, Hee-Jin | - |
dc.contributor.author | Moon, Kyung Chul | - |
dc.contributor.author | Ban, Tae Hyun | - |
dc.contributor.author | Oh, Se Won | - |
dc.contributor.author | Jo, Sang Kyung | - |
dc.contributor.author | Cho, Heeyeon | - |
dc.contributor.author | Choi, Bum Soon | - |
dc.contributor.author | Hong, Junshik | - |
dc.contributor.author | Cheong, Hae Il | - |
dc.contributor.author | Oh, Doyeun | - |
dc.date.accessioned | 2021-08-31T14:59:21Z | - |
dc.date.available | 2021-08-31T14:59:21Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-01 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/58464 | - |
dc.description.abstract | Thrombotic microangiopathy (TMA) is defined by specific clinical characteristics, including microangiopathic hemolytic anemia, thrombocytopenia, and pathologic evidence of endothelial cell damage, as well as the resulting ischemic end-organ injuries. A variety of clinical scenarios have features of TMA, including infection, pregnancy, malignancy, autoimmune disease, and medications. These overlapping manifestations hamper differential diagnosis of the underlying pathogenesis, despite recent advances in understanding the mechanisms of several types of TMA syndrome. Atypical hemolytic uremic syndrome (aHUS) is caused by a genetic or acquired defect in regulation of the alternative complement pathway. It is important to consider the possibility of aHUS in all patients who exhibit TMA with triggering conditions because of the incomplete genetic penetrance of aHUS. Therapeutic strategies for aHUS are based on functional restoration of the complement system. Eculizumab, a monoclonal antibody against the terminal complement component 5 inhibitor, yields good outcomes that include prevention of organ damage and premature death. However, there remain unresolved challenges in terms of treatment duration, cost, and infectious complications. A consensus regarding diagnosis and management of TMA syndrome would enhance understanding of the disease and enable treatment decision-making. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | - |
dc.subject | NOVO THROMBOTIC MICROANGIOPATHY | - |
dc.subject | ANTIBODY-MEDIATED REJECTION | - |
dc.subject | RENAL-TRANSPLANTATION | - |
dc.subject | THERAPEUTIC APHERESIS | - |
dc.subject | WRITING COMMITTEE | - |
dc.subject | AMERICAN SOCIETY | - |
dc.subject | ADULT PATIENTS | - |
dc.subject | ECULIZUMAB | - |
dc.subject | GUIDELINES | - |
dc.subject | INHIBITION | - |
dc.title | Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh, Se Won | - |
dc.identifier.doi | 10.3904/kjim.2019.388 | - |
dc.identifier.scopusid | 2-s2.0-85077845091 | - |
dc.identifier.wosid | 000505206100003 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, v.35, no.1, pp.25 - 40 | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.title | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.volume | 35 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 25 | - |
dc.citation.endPage | 40 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002538467 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | NOVO THROMBOTIC MICROANGIOPATHY | - |
dc.subject.keywordPlus | ANTIBODY-MEDIATED REJECTION | - |
dc.subject.keywordPlus | RENAL-TRANSPLANTATION | - |
dc.subject.keywordPlus | THERAPEUTIC APHERESIS | - |
dc.subject.keywordPlus | WRITING COMMITTEE | - |
dc.subject.keywordPlus | AMERICAN SOCIETY | - |
dc.subject.keywordPlus | ADULT PATIENTS | - |
dc.subject.keywordPlus | ECULIZUMAB | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordAuthor | Thrombotic microangiopathies | - |
dc.subject.keywordAuthor | Atypical hemolytic uremic syndrome | - |
dc.subject.keywordAuthor | Complement pathway | - |
dc.subject.keywordAuthor | alternative | - |
dc.subject.keywordAuthor | Diagnosis | - |
dc.subject.keywordAuthor | differential | - |
dc.subject.keywordAuthor | Eculizumab | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.